S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
FB   201.34 (+0.14%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
AMZN   1,749.51 (-0.12%)
CGC   21.29 (+14.16%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.74 (-1.56%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
T   38.04 (-0.42%)
AMD   38.93 (-1.77%)
ACB   2.62 (+7.82%)
F   9.01 (-0.11%)
PRI   135.35 (-0.24%)
NFLX   302.50 (-1.58%)
BAC   33.51 (-0.48%)
GILD   66.93 (-0.22%)
DIS   146.21 (-0.98%)
Log in

NASDAQ:KIDS - Orthopediatrics Stock Price, Forecast & News

$38.62
-0.62 (-1.58 %)
(As of 12/9/2019 04:00 PM ET)
Today's Range
$37.67
Now: $38.62
$39.34
50-Day Range
$35.77
MA: $38.06
$39.80
52-Week Range
$28.19
Now: $38.62
$47.82
Volume66,200 shs
Average Volume73,846 shs
Market Capitalization$576.98 million
P/E RatioN/A
Dividend YieldN/A
Beta0.21
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KIDS
CUSIPN/A
Phone574-268-6379

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$57.56 million
Book Value$6.38 per share

Profitability

Net Income$-12,020,000.00

Miscellaneous

Employees80
Market Cap$576.98 million
Next Earnings Date3/4/2020 (Estimated)
OptionableNot Optionable

Receive KIDS News and Ratings via Email

Sign-up to receive the latest news and ratings for KIDS and its competitors with MarketBeat's FREE daily newsletter.


Orthopediatrics (NASDAQ:KIDS) Frequently Asked Questions

What is Orthopediatrics' stock symbol?

Orthopediatrics trades on the NASDAQ under the ticker symbol "KIDS."

How were Orthopediatrics' earnings last quarter?

Orthopediatrics Corp (NASDAQ:KIDS) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The firm had revenue of $20.74 million for the quarter, compared to the consensus estimate of $19.87 million. Orthopediatrics had a negative return on equity of 12.12% and a negative net margin of 15.80%. Orthopediatrics's quarterly revenue was up 31.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.15) EPS. View Orthopediatrics' Earnings History.

When is Orthopediatrics' next earnings date?

Orthopediatrics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Orthopediatrics.

What guidance has Orthopediatrics issued on next quarter's earnings?

Orthopediatrics updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$71.37316-71.94875 million, compared to the consensus revenue estimate of $$71.33 million.

What price target have analysts set for KIDS?

4 equities research analysts have issued twelve-month price objectives for Orthopediatrics' stock. Their forecasts range from $44.00 to $53.00. On average, they expect Orthopediatrics' share price to reach $46.25 in the next year. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Orthopediatrics.

What is the consensus analysts' recommendation for Orthopediatrics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orthopediatrics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orthopediatrics.

What are Wall Street analysts saying about Orthopediatrics stock?

Here are some recent quotes from research analysts about Orthopediatrics stock:
  • 1. According to Zacks Investment Research, "OrthoPediatrics Corp. is a medical device company. It markets surgical systems for trauma and deformity, bone fractures and reconstruction procedures. OrthoPediatrics Corp. is based in NEW YORK. " (11/15/2019)
  • 2. BTIG Research analysts commented, "We maintain our Buy rating and $44 PT following 1Q19 results which saw softer than anticipated Trauma & Deformity sales resulting from weakness in elective deformity procedures. Overall rev. was in-line with BTIG/Street estimates of $14.8M/$14.7M as continued strength in Scoliosis offset T&D softness (~$900k estimated). Despite the 1Q weakness, mgmt. noted that KIDS had not lost share nor seen competitive encroachment and that deformity procedure volumes have come back noticeably in 2Q to date. That said, at KIDS’ multiple we feel shares will be pressured at least until the bounce-back in volume is seen in 2Q. We continue to view a significant market opportunity, a robust pipeline (both organically and inorganically), and limited competition as able to support continued 20%+ growth (here)." (5/10/2019)

Has Orthopediatrics been receiving favorable news coverage?

News stories about KIDS stock have been trending somewhat negative on Monday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Orthopediatrics earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Orthopediatrics.

Are investors shorting Orthopediatrics?

Orthopediatrics saw a increase in short interest in October. As of October 15th, there was short interest totalling 1,130,000 shares, an increase of 5.6% from the September 15th total of 1,070,000 shares. Based on an average daily volume of 71,500 shares, the short-interest ratio is currently 15.8 days. Approximately 12.8% of the shares of the company are sold short. View Orthopediatrics' Current Options Chain.

Who are some of Orthopediatrics' key competitors?

What other stocks do shareholders of Orthopediatrics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthopediatrics investors own include Akorn (AKRX), Advanced Micro Devices (AMD), Intel (INTC), AbbVie (ABBV), Boeing (BA), Freeport-McMoRan (FCX), Honeywell International (HON), Nike (NKE), New Residential Investment (NRZ) and ArQule (ARQL).

Who are Orthopediatrics' key executives?

Orthopediatrics' management team includes the folowing people:
  • Mr. Mark C. Throdahl, Pres, CEO & Director (Age 68)
  • Mr. Fred L. Hite, CFO & Director (Age 51)
  • Mr. Daniel J. Gerritzen, VP of Legal & HR, Gen. Counsel and Sec. (Age 49)
  • Mr. David R. Bailey, Exec. VP (Age 40)
  • Mr. Gregory A. Odle, Exec. VP of Commercialization (Age 49)

When did Orthopediatrics IPO?

(KIDS) raised $52 million in an initial public offering on Thursday, October 12th 2017. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.

Who are Orthopediatrics' major shareholders?

Orthopediatrics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (4.50%), Riverbridge Partners LLC (3.43%), State Street Corp (1.08%), Roubaix Capital LLC (0.81%), Granahan Investment Management Inc. MA (0.60%) and Millennium Management LLC (0.48%). Company insiders that own Orthopediatrics stock include Daniel J Gerritzen, David R Bailey, David R Pelizzon, Fred Hite and Kevin Unger. View Institutional Ownership Trends for Orthopediatrics.

Which institutional investors are selling Orthopediatrics stock?

KIDS stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Millennium Management LLC, State Street Corp and Barclays PLC. View Insider Buying and Selling for Orthopediatrics.

Which institutional investors are buying Orthopediatrics stock?

KIDS stock was acquired by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Riverbridge Partners LLC, Roubaix Capital LLC, Granahan Investment Management Inc. MA, Squarepoint Ops LLC, Envestnet Asset Management Inc., Oppenheimer Asset Management Inc. and Conestoga Capital Advisors LLC. View Insider Buying and Selling for Orthopediatrics.

How do I buy shares of Orthopediatrics?

Shares of KIDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Orthopediatrics' stock price today?

One share of KIDS stock can currently be purchased for approximately $38.62.

How big of a company is Orthopediatrics?

Orthopediatrics has a market capitalization of $576.98 million and generates $57.56 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Orthopediatrics employs 80 workers across the globe.View Additional Information About Orthopediatrics.

What is Orthopediatrics' official website?

The official website for Orthopediatrics is http://www.orthopediatrics.com/.

How can I contact Orthopediatrics?

Orthopediatrics' mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The company can be reached via phone at 574-268-6379 or via email at [email protected]


MarketBeat Community Rating for Orthopediatrics (NASDAQ KIDS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  452
MarketBeat's community ratings are surveys of what our community members think about Orthopediatrics and other stocks. Vote "Outperform" if you believe KIDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIDS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel